# **HEAR LIFE TO THE FULLEST**

JP MORGAN HEALTHCARE CONFERENCE

**JANUARY 12, 2021** 

# FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation are forward-looking statements, including statements regarding our preliminary unaudited net revenue and preliminary gross systems shipped for the fourth quarter and year ended December 31, 2020. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: completion of our financial closing procedures and any adjustments that may result from the completion of the annual independent audit of our consolidated financial statements; our expectations concerning additional orders by existing customers; our expectations regarding the potential market size and size of the potential consumer populations for our products and any future products, including our ability to increase insurance coverage of Eargo hearing aids; our ability to release new hearing aids and the anticipated features of any such hearing aids; developments and projections relating to our competitors and our industry, including competing products; our ability to maintain our competitive technological advantages against new entrants in our industry; the pricing of our hearing aids; our expectations regarding the ability to make certain claims related to the performance of our hearing aids relative to competitive products; our expectations with regard to changes in the regulatory landscape for hearing aid devices, including the implementation of the pending over-the-counter hearing aid pathway regulatory framework; and our estimates regarding the COVID-19 pandemic, including but not limited to, its duration and its impact on our business and results of operations. These and other risks are described in greater detail under the section titled "Risk Factors" contained in Eargo's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 20, 2020 and the company's other filings with the SEC. Any forward-looking statements in this presentation are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this presentation. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

# TRANSFORMING THE HEARING AID INDUSTRY

#### Large Market with Significant Unmet Need

 $\checkmark$  43M U.S. adults have hearing loss<sup>1,2</sup>, but only ~27% owned a hearing aid in 2019<sup>3</sup>

#### Low Penetration Due To


- Stigma of visible hearing aids (~88% of 2019 U.S. market)  $\checkmark$
- Discomfort of existing in-the-ear hearing aids (~12% of 2019 U.S. market)  $\checkmark$
- ✓ High cost
- Inconvenient, cumbersome experience; many visits to the audiologist


#### **Eargo Addresses This Unmet Need**

- Virtually invisible, in-the-ear, FDA regulated, exempt product; high-guality audio
- Comfortable, all-day wear  $\checkmark$
- Lower cost to consumer
- Efficient, DTC model offers education, purchase and telecare support from home  $\checkmark$

#### **Strong Financial Profile**<sup>4</sup>

- ✓ ~\$22.2M 4Q20 preliminary unaudited net revenue, up approximately 109% YoY
- ✓ ~\$69.0M FY20 preliminary unaudited net revenue, up approximately 110% YoY
- Prevalence of Hearing Loss by Severity in the United States, Adele M. Goman, PhD, and Frank R. Lin, MD, PhD, 2016
- U.S. Census International Database
- Hearing Review; Hearing Industries Association, Industry reports; Eargo estimates





## LARGE, UNDERPENETRATED MARKET

# ŤŤŤŤŤŤŤŤ

#### 43M U.S. ADULTS WITH HEARING LOSS




ANNUAL U.S. HEARING AID SALES IN 20191

### But only ~27% own a hearing aid

## WHY?

- ✓ HIGH STIGMA
- ✓ HIGH COST
- ✓ HIGHLY INCONVENIENT

## MILD AND MODERATE HEARING LOSS: 94% OF U.S. MARKET



1. Lin, F. R., Niparko, J. K., & Ferrucci, L. (2011). Hearing Loss Prevalence in the United States. Archives of Internal Medicine, 171(20), 1851–1852.; Prevalence of Hearing Loss by Severity in the United States, Adele M. Goman, PhD, and Frank R. Lin, MD, PhD, 2016

- 2. .Prevalence of Hearing Loss by Severity in the United States, Adele M. Goman, PhD, and Frank R. Lin, MD, PhD, 2016
- 3. U.S. Census Bureau, Current Population Survey, 2019 Annual Social and Economic Supplement.

4. ~14M consumers multiplied by Eargo average selling price of \$2,200

## **TRADITIONAL HEARING AIDS HAVE SIGNIFICANT LIMITATIONS**

	Behind-the-ear hearing aids		In-the-ear hearing aids			
	BEHIND-THE-EAR MINI BTE		IN-EAR	IN-CANAL		
			<u>S</u>	$\sum$		
	Approximately 88%	market share <sup>1</sup>	Approximately 12	2% market share <sup>1</sup>		
APPLICABILITY	Fit the widest range of hearing loss		Mild to severe	Mild to severe hearing loss		
VISIBILITY	Most vis	sible	Less	visible		
COMFORT AND OCCLUSION	Most comfortable and least occlusive		Very occlusive			
RECHARGEABILITY	Som	e	Some	None		
AVERAGE COST		\$4,6	00 <sup>2</sup>			
TRIAL PERIOD		Varies; avera	ge ~48 Days³			

1 Hearing Industries Association

2 Represents estimated average retail costs per pair of hearing aids sold through traditional channels in the United States. Hearing aids with custom features that reduce device visibility or improve comfort can retail for significantly more than the industry average. 3 Industry data, Eargo estimates

## EARGO ADDRESSES THESE LIMITATIONS



TRADITIONAL HEARING AIDS	EARGO
STIGMATIZED, VISIBLE, UNATTRACTIVE	VIRTUALLY INVISIBLE
EAR CANAL OCCLUSION, DISCOMFORT	COMFORTABLE, NON-OCCLUSIVE
BATTERY CHANGING HASSLE	C RECHARGEABLE, EASY-TO-USE
DISEMPOWERING, CUMBERSOME PROCESS	EMPOWERING, CONSUMER-CENTRIC PROCESS
B2B, LAYERS OF COST	OTC, VERTICALLY INTEGRATED
\$4,600 AVERAGE COST <sup>1,2</sup>	\$1,850 - \$2,950 <sup>2</sup>

## "FIRST AND ONLY" TECHNOLOGY; TELECARE SUPPORT

#### **Eargo Hearing Aid**

(Close-up View)



Patented FlexiPalm design provides comfortable, non-occluding fit



High quality audio comparable to BTE devices from major manufacturers<sup>1</sup>



Up to 16 hours of rechargeable battery life



Body

Microphone Cover

Removal Thread



\*Only available on Neo and Neo HiFi



Flexi Palm

(includes Primary Wax Filter)

#### Personalized, Telecare Support



Unlimited, lifetime support from licensed hearing professionals



No clinic visits: interact via phone, email, text or video




Real-time audio profile personalization via the internet\*




1. Based on Eargo internal comparative electroacoustic bench tests measuring Eargo Neo against Starkey Livio Al 2400, the Phonak Audeo Marvel M90, and the Resound Linx Quattro 5, all behind-the-


## **HIGH-QUALITY SOUND AND AMPLIFICATION**




Should include 250 to 6000 Hz to cover the complete range of speech



Should be below 3% for all frequencies tested



Should provide appropriate amplification for a specific hearing loss, as determined by the Audioscan Verifit test system



Should be below 28 dB SPL

Eargo internal comparative electroacoustic bench tests measuring Eargo Neo against Starkey Livio AI 2400, the Phonak Audeo Marvel M90, and the Resound Linx Quattro 5, all behind-the-ear (BTE) style hearing aids with receiver-in-the-canal (RIC).

## HIGH CADENCE OF PURPOSEFUL INNOVATION


#### 2Q21^

**EARGO** NEO HIFI

+ Improved fidelity,

+ Improved Flexi Palms

- EARGO Next Generation
- + Improved fit and output
- + In-situ hearing assessment and adjustments
- + Increased water resistance
- + Refurbishment capability



# **TELECARE MODEL TRANSFORMS CONSUMER JOURNEY**




# EARGO TELECARE MODEL

#### **Unlimited Lifetime Support**

- Initial consultation
- Hearing screening / results analysis
- ✓ Guidance on proper insertion, charging and cleaning
- Real-time audio settings modification for individual hearing loss
- Provided Telecare to 80% of customers within first month of product ownership for the nine months ended September 30, 2020





9:07 <del>-1</del> 🕈 🗔 -	My Programs	Edit	K Bass &	Treble	<	Programs	
< Contact Eargo	1 Preset A		1 Preset A Adjust for both ears of to adjust separately.		0	<b>A</b> 3	4
	(++) Bass & Treble		Both	Left/Right	Program 1		
EMAIL Email Eargo Support	2 Preset B		+ •	• +	<b>دے۔</b> Meeting	දිදුයි Crowd	X Restaurant
	Bass & Treble Preset C		0.	- 0	() Theater	Phone	Ŭ TV
S	Bass & Treble			_	A Preset A	B Preset B	C Preset C
PHONE Talk with Eargo Support	4 Preset D		Bass	Treble	D Preset D	⊄]× Mute	
	H Bass & Treble						
VIDEO							
Schedule an in app video call with Eargo Support	Apply		Do	ne		Done	
							4.0

# **EFFICIENT, MULTI-CHANNEL CUSTOMER ACQUISITION**

ead Collection	Inbound Phone		<b>Lead Form</b> (Web)	<b>Direct Purchase</b> (Web)	
Lead Conversion	Sales Consultants/ Hearing Profession		Online Hearing Assessment	Online Experience	
			Email / Text / Chat	Promotions	
Customer Type	Cash Pay	Insurance	Repeat Purchases	Retail Experience via Partnerships (Future)	

SP.

# **EFFICIENT CUSTOMER ECONOMICS**

#### **Cash Pay**

- Customer pays for hearing aid out of pocket
- Most common way to get a hearing aid but no longer the only way

# Conversion Rate Customer ASP Return Rate Image: Conversion Rate Image: Customer ASP Image: Custo

#### Insurance

- Customer reimbursed for some or all of hearing aid cost
- ~12M in the U.S. over 50 who have both hearing loss and access to hearing aid benefits under certain health insurance plans<sup>1,2</sup>
- Eargo provides national claims processing

#### Repeat (Cash Pay)


- Substantial portion of traditional hearing aid purchases are repeat customers
- Eargo installed base of ~16,000 units >2 years old<sup>3</sup>



Eargo has achieved only limited coverage of Eargo hearing aids under these health insurance plans, and Eargo intends to pursue additional coverage in the future. As of December 31. 2020

# ESTIMATED 4Q AND FY20 FINANCIAL PERFORMANCE<sup>1</sup>

#### ~110% YOY GROWTH



#### **Revenue Drivers**

- Increased consumer demand during holiday buying season
- Strong performance of national advertising
- Further penetration of insurance market
- Increased acceptance of telecare model

#### Estimated FY20 Results

- FY20 preliminary unaudited revenues of approximately \$69.0M, up approximately 110% YoY
- FY20 preliminary gross shipments of approximately 38,200, up approximately 68% YoY

1. Our consolidated financial statements for the three and twelve months ended December 31, 2020 are not yet available. Accordingly, the information presented for these periods reflects our preliminary estimates that could differ and are subject to the completion of our financial closing procedures and any adjustments that may result from the completion of the annual independent audit of our consolidated financial statements. Once our financial closing procedures and annual independent audit are completed, we may report financial results and other data that could differ from these preliminary results and data. Our independent registered public accounting firm has not audited, reviewed, compiled or performed any procedures with respect to such preliminary results.

THANK YOU